buy ripretinib nda file ahead
messag today announc file new drug applic nda ripretinib
came ahead schedul previou guidanc review via
fda real-tim oncolog review rtor program posit news may
expedit ripretinib potenti approv launch time previous
assum approv initi launch base assum nda
file updat estim account sooner-than-previ expect approv
time maintain buy pt
submit ripretinib nda ahead schedul fda review real-tim
oncolog review rtor program may expedit timelin potenti approv recal
obtain breakthrough therapi design btd link ripretinib
read compel phase result gist link link previous guid
nda file fda review ripretinib rtor could repres potenti
expedit time-to-approv rel prioriti review confer via btd given
recent rtor nda approv novn piqray breast cancer month
nda submiss approv sbla snda applic
adcetri peripher t-cell lymphoma day sbla submiss link
mrk/esali keytruda lenvima endometri cancer month snda/sbla
submiss erleada mcnpc month snda submiss
updat estim account potenti expedit timelin maintain
buy pt advanc ripretinib launch time assumpt
previous given earlier-than-expect nda file review rtor
program model pos-adjust us sale ripretinib gist assum
po gist phase intrigu trial po gist peak market share
assumpt gist respect pt remain
page analyst certif import disclosur
valuat risk
valuat per share base probability-adjust estim gist
net cash balanc sheet year use discount cash flow analysi
use wacc termin growth rate appli termin year post-assum
gener entri
risk rate valuat includ regulatori commerci setback
potenti emerg new competitor lower product sale expect cash flow-
neg compani may also engag financ activ dilut exist
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
page analyst certif import disclosur
